Skip to main content
. 2022 May 16;132(10):e145343. doi: 10.1172/JCI145343

Figure 4. PRAME restoration and Pr20 antibody binding enhancement by EZH2 inhibition.

Figure 4

(A) PRAME real-time PCR of EPZ-6438–treated cell lines in 3 concentrations (0, 1, 5 μM) (Bonferroni’s multiple-comparison test, mean ± SEM, **P < 0.01). Data were normalized to expression values of the no-treatment control (0 μM). (B) Representative immunoblotting of EPZ-6438–treated cell lysates in 6 concentrations (0, 0.1, 0.5, 1, 2, 5 μM) for WSU-DLCL2 (EZH2 mut) and HT, HBL-1 (EZH2 WT) cell lines. EZH2 inhibition was evaluated by H3K27me3 immunoblotting. (C) Pr20 antibody binding enhancement using EPZ-6438, IFN-γ, and the combination of EPZ-6438 and IFN-γ.